Kidney Cancer News Archive
In 2015, 69% of surgeries for prostate, bladder, and kidney cancer were performed with robotic assistance, a new meta-analysis shows.
New findings from the CARMENA trial contradict previous research showing better survival from cytoreductive nephrectomy followed by targeted therapy.
Patients in the highest quintile of urinary albumin excretion had a 4.5-fold increased risk of urothelial cell carcinoma vs those in quintiles 1-3.
Race, procedure and insurance type, sex, surgeon volume, and hospital size influence the risk of readmission among patients undergoing radical nephrectomy, study finds.
In a study of mRCC patients who received targeted therapy (TT) following cytoreductive nephrectomy, mortality risk did not differ significantly between delayed and early TT.
Black patients tended to have lower incomes, less education, longer delays to treatment, greater comorbidity burden.
Study shows that partial nephrectomy for small renal tumors is associated with lower risk of cancer-specific and other-cause mortality in patients aged 75 years and older.
Men and women who smoke are at 2.3-fold and 2.7-fold increased risk of bladder cancer compared with non-smokers.
Doctors who receive general payment for cancer drug more likely to prescribe drug marketed by company.
An evaluation of patients with clear cell renal cell carcinoma revealed greater risk of death for female patients with high relative visceral fat area (rVFA), highlighting the significance of metabolic differences between men and women.
Myocarditis with ICIs may be more common than initially thought; responds to higher steroid dosages
The risk of dying from pT1a renal cell carcinoma after partial or radical nephrectomy increases along with patient age.
Among intermediate- and poor-risk patients, the risk for death was 37% lower with nivolumab plus ipilimumab than with sunitinib.
Two-year recurrence-free survival was 100% vs 95.2% among robotic surgery and radiofrequency ablation patients, respectively.
Not reliable predictor of adverse outcomes in those under active surveillance; less variability over time
Treatment-naïve patients with advanced clear-cell renal cell carcinoma had significantly longer progression-free survival when treated with pazopanib instead of temsirolimus.
The safety and efficacy of nivolumab for treating metastatic renal cell carcinoma is comparable to that found in the CheckMate 025 trial.
In a phase Ib study, dual therapy with axitinib and pembrolizumab was well tolerated and demonstrated antitumor activity in treatment-naïve patients with advanced renal cell carcinoma.
Study reveals a 38% decreased risk of death in patients with papillary metastatic renal cell carcinoma who undergo cytoreductive nephrectomy vs those who do not.
Immunotherapy with atezolizumab plus targeted therapy with bevacizumab improves progression-free survival better than sunitinib in patients with untreated metastatic renal cell carcinoma.
In a study, nearly 20% of radical cystectomy patients were readmitted for complications within 90 days compared with 1.9% and 5.9% for radical prostatectomy and radical nephrectomy, respectively.
No greater risks for upstaging or positive surgical margins were observed among patients who underwent RPN for cT2a tumors over the short term.
Elevated serum levels of BNP and NT-proBNP prior to nephrectomy are associated with an increased likelihood of RCC progression.
Access to treatment should be considered as important as the research leading to clinical improvements.
Patients who underwent radical nephrectomy had 2-fold greater decline in eGFR decline and 2-fold greater mortality compared with those who had a partial nephrectomy.
Patients who received cabozantinib were also less likely to have skeletal-related events (23% vs 29% with everolimus).
Stereotactic ablative radiotherapy is associated with high 2- and 4-year rates of local cancer control and progression-free and cancer-specific survival.
In a multinational, prospective study, just 5% of cases converted.
Most patients with cancer, autoimmune disease have improvement in events without discontinuing therapy.
Although TKIs improve outcomes, they are still associated with toxicities common with cancer therapies, such as fatigue.
Partial nephrectomy was associated with decreased odds of death versus radical nephrectomy among patients with cT1b but not cT2 renal cell carcinoma.
Treatment with cabozantinib led to a clinically meaningful improvement in progression-free survival compared with sunitinib.
Patients who underwent cytoreductive nephrectomy for metastatic non-clear cell renal cell carcinoma had a significantly decreased risk of cancer-related mortality.
Levels of alkaline phosphatase, calcium, and hemoglobin can independently predict bone metastasis in patients with renal cell carcinoma, Chinese investigators report.
Propensity score matching showed a 5.8 month survival advantage for initial CN vs initial systematic therapy.
At 5 years, 59.3% of patients treated with sunitinib were free from recurrence versus 51.3% who received placebo.
Robotic-assisted radical nephrectomy (RN) is associated with higher hospital costs and prolonged operating time compared with laparoscopic RN.
Perioperative blood transfusion is associated with increased risks of tumor recurrence, metastatic progression, and cancer-related mortality.
40% of cancer diagnoses tied to extra weight; rate higher in older individuals, females.
Patients with papillary versus clear cell renal cell carcinoma have a 24% decreased risk of dying from their cancer.
In a study, partial nephrectomy was associated with a 66% lower risk for stage 4 or higher CKD versus radical nephrectomy.
The researchers found that 2.9% of the 347 patients treated with anti-PD-1 monoclonal antibodies developed subacute onset of neurological complications.
Mvasi, which is approved to treat colorectal, lung, brain, kidney, and cervical cancer, was found to be biosimilar to the drug Avastin.
Checkpoint inhibitor combination of nivolumab plus ipilimumab improved progression-free and overall survival compared with sunitinib.
Cabozantinib reduced the risk of disease progression or death compared with sunitinib among patients with previously untreated advanced renal cell carcinoma.
Rises and decreases in neutrophil-to-lymphocyte ratio at 6 weeks after treatment with anti-PD-1/PD-L1 immune checkpoint blockade is associated with progression-free and overall survival.
The increased risk for obesity-related cancer was seen among women who were normal weight at enrollment.
Participant age and comorbidity burden appeared to be consistent determinants of use of services, although hospital-level variation was also noted.
The most commonly altered genes were folliculin and fumarate hydratase in 1.8% and 1.3%, respectively.
Patients who have a complete response to 2 or more years of anti-VEGF treatment have the best progression-free and overall survival.
BMI and location of excess body fat on the body are good indicators of obesity-related cancer risk.
Renal and bladder cancer patients were, respectively, 77% and 73% more likely to report lifetime physical inactivity than controls without cancer.
The document spells out in greater detail the criteria for radical and partial nephrectomy and for placing patients on active surveillance.
Changes in C-reactive protein levels 4 weeks after starting sunitinib or sorafenib treatment are associated with overall and progression-free survival.
In a single-center study, 24% of patients crossed over to treatment and 95% of patients were alive after 5 years of follow-up.
Nivolumab treatment beyond disease progression results in reductions in tumor burden, study finds.
In a study, the 5-year risk of recurrence was 4.8%, 18.1%, and 46.3% for patients with low-, intermediate-, and high-risk disease.
Patients who used the drug had a 38% lower risk of dying from kidney cancer than non-users, meta-analysis shows.
Overall survival among patients receiving first-line targeted therapy for advanced renal cell carcinoma increased significantly from 2006 to 2012.
Study also finds associations between adiposity and 10 other cancers, particularly digestive and hormone-related malignancies.
The researchers found that patients treated with ABT had decreased progression-free survival compared with those not receiving ATB.
In a phase 2 trial, atezolizumab plus bevacizumab improved PFS versus sunitinib in patients with renal cell carcinoma expressing PD-L1.
Added progression-free survival and prolonged overall survival possible, according to investigators.
Researchers develop a model to predict which patients are more likely to harbor brain metastases at cancer diagnosis.
Bone surgery should be considered in patients with solitary bone metastasis and no concomitant visceral metastases, according to investigators.
In a pilot study, metabolomic analyses of serum and urine showed a high level of predictive ability.
All patients with an SRM should be considered for a biopsy when the results may alter management.
The most common types of benign pathology were oncocytoma, angiomyolipoma, and complex cysts.
In a study, only 3 of 108 patients experienced complications, all of which were minor and required no hospitalization or further intervention.
In 2013, nearly one third of all minimally invasive radical nephrectomies were performed with robotic assistance.
Partial and radical nephrectomy were associated with similar cancer-specific and overall survival in elderly patients.
In the 15 patients in the study, the dual treatment controlled tumors in 93% of the patients, who had either clear cell or papillary renal cell cancer.
Cancer patients diagnosed in their teens had a more than 4-fold higher risk of death from cardiac disease than patients who didn't have cancer.
Robotic partial nephrectomy confers a superior morbidity profile compared to laparoscopic partial nephrectomy.
Among patients with clear-cell renal-cell carcinoma at high risk for tumor recurrence, the duration of disease-free survival was significantly longer in the sunitinib group.
Prediagnosis obesity is a risk factor for overall and individual secondary primary cancers.
Use of the drug is associated with significantly longer progression-free survival compared with suninitib in treatment-naïve patients.
Study of US veterans reveals, however, that the procedure is being used less in subgroups who might benefit the most.
In a small study, researchers observed a decrease in tumor burden and extended duration of therapy.
Immunotherapy treatments for patients with bladder cancer, head and neck cancer, Hodgkin's lymphoma, and kidney cancer, is useful against malignancy, according to Cancer Progress Report.
The recurrence group had significantly larger tumors than the no-recurrence group.
Open partial nephrectomy had a significantly higher rate of complications.
Paradoxical association could be related to an altered fatty acid pathway.
International committee finds slimmer individuals less likely to develop variety of malignancies.
Robotic surgery may offer some benefits, such as shorter hospital stay and less blood loss.
Mean exposure of 18.80 mg/m3 per year was associated with a significant 11% increased risk among white men.
Some metastatic RCC patients may safely undergo surveillance prior to starting systematic therapy.
Research results provide potential new targets for combination therapy regimens.
Study finds no increased risk of overall complications in patients undergoing robotic partial nephrectomy.
Findings in patients treated for T1a renal cell carcinoma followed with X-ray surveillance.
Patients whose surgical wait time was 3 months or more versus less than 3 months had 10-fold increased odds of having a smaller tumor.
Disseminated cancer at the time of radical nephrectomy is associated with 2-fold increased odds of major perioperative complications.
Most patients discharged home within first 6 hours after surgery; none readmitted.
The drug significantly improves overall and progression-free survival compared with everolimus, researchers report.
The optimal tumor shrinkage threshold for predicting overall and progression-free survival is 10%, researchers concluded.
Four key lifestyle factors include weight, exercise, no smoking, and limiting alcohol.
Findings for self-reported leisure-time physical activity of moderate to vigorous intensity.
The risk is most elevated among individuals aged 44 years or younger.
Nearly 6% of patients who underwent partial or radical nephrectomy between 1998 and 2010 developed AKI.
About 25% of patients who present with metastatic renal cancer will undergo nephrectomy after diagnosis.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)